摘要
目的评价恩替卡韦联合安络化纤丸治疗慢性乙型肝炎(乙肝)肝纤维化的疗效。方法慢性乙肝肝纤维化患者85例,随机分为2组:治疗组43例,口服恩替卡韦片0.5mg,qd;安络化纤丸6g,tid;对照组42例,口服恩替卡韦片0.5mg,qd,两组疗程均为1a。分别于治疗前、后进行肝功能、肝纤维化血清学指标检测及超声影像学检查。结果治疗1a后,①2组患者肝功能、肝纤维化指标和超声影像学指标均有不同程度好转;②治疗组血清清蛋白(ALB)升高幅度较对照组高(P<0.05);③治疗组肝纤维化指标和超声影像学指标(脾厚度)方面的改善较对照组明显(P<0.05)。结论恩替卡韦联合安络化纤丸抗慢性乙肝肝纤维化疗效更好。
Objective To evaluate the clinical therapeutic effect of entecavir combined with anluo huaxian pills on hepatic fibrosis of chronic hepatitis B. Methods 85 patients with hepatic fibrosis were randomly divided into entecavir treated group（43,qd,0.5 mg） and entecavir（0.5 mg,qd） combined with anluo huaxian pills（6 g,tid） treated group （42）. The liver function,serum markers of hepatic fibrosis and ultrasonographic image were compared before and after treatment. Results After 1 year＇s treatment,①the liver function,liver fibrosis index and ultrasonographic image of two groups were improved in different degrees; ② the improvement of ALB in the combination treatment group was more significant than those in single treatment group（P0.05）; ③ The liver fibrosis index（HA、PCⅢ、C-Ⅳ）and the ultrasonographic image （the thickness of spleen）were better in two drugs treated group than in entecavir group（P0.05）. Conclusion Entecavir combined with anluo huaxian pills possesses more effective antifibrotic effect on hepatic fibrosis of chronic hepatitis B.
出处
《医药导报》
CAS
2010年第9期1157-1159,共3页
Herald of Medicine
关键词
恩替卡韦
安络化纤丸
肝炎
乙型
慢性
肝纤维化
Entecavir
Anluo huaxian pills
Hepatitis B
chronic
Hepatic fibrosis
